0001104659-26-057198
SEC filingProfound Medical reported Q1 revenue of $5.3M, up 103.6% from $2.6M, driven by higher capital equipment sales that expanded gross profit to $3.8M at 71.8% margin. Operating and net losses narrowed to -$8.0M and -$7.1M respectively as revenue growth outpaced expense increases from commercialization.
Profound Medical Corp. delivered strong Q1 2026 top-line growth with revenue reaching $5.3 million, a 103.6% increase from $2.6 million in Q1 2025. This acceleration stemmed from heightened demand for TULSA-PRO and Sonalleve systems, particularly capital equipment sales in U.S. and overseas markets alongside recurring device revenue. The shift in product mix toward higher-margin capital equipment directly fueled gross profit expansion to $3.8 million, up 106.8% from $1.9 million, achieving a robust 71.8% gross margin—consistent with the prior period's 71% level noted in management commentary.
Despite revenue gains, operating income remained negative at -$8.0 million, an improvement of 28.2% from the prior year's -$11.2 million. This narrowing reflects revenue scale partially offsetting elevated operating costs tied to commercialization efforts. Management highlighted increased headcount, travel, clinical trial costs, and marketing fees as key drivers of cash used in operations, which ticked up slightly to -$8.6 million from -$8.3 million. These investments support broader product expansion, enabling the company to capture market share in MRI-guided therapies.
Net income loss moderated to -$7.1 million from -$10.7 million, a 34.2% improvement, with diluted EPS at $0.19 versus $0.36. The better bottom-line result was aided by favorable other income dynamics: a decrease in net finance expense due to lower interest income on cash balances, partially offset by higher net foreign exchange losses from EUR and CAD currency fluctuations. Operating margin stood at -150.3%, underscoring the company's investment phase.